Israel Active

Israel’s Therapix Biosciences (reported previously) is working with the University of Calgary to evaluate the pain relief effect of its THX-160 analgesic. In pre-clinical studies, THX-160 was in some instances even more effective than high-dose morphine.

Israel’s Sol-Gel (reported previously) has had its Twyneo acne treatment US FDA-approved following successful Phase 3 testing.

Israel’s Theranica (reported previously) has received US FDA clearance to market its Nerivio therapeutic device for the acute treatment of episodic or chronic migraine in people 12 years and older. Theranica’s migraine patch was approved by the FDA in 2019.

Amazing new research in which scientists at Israel’s Weizmann Institute have studied how the body responds to stress on a cell-by-cell basis. They have mapped the “stress axis” and the production of the hormone cortisol. The research opens up avenues to new treatments for chronic stress.

Scientists from Bar Ilan University, Harvard and MIT have produced a detailed map of the genes inside the main memory center of a mouse brain. The researchers say the same technology will work in humans and could help treat diseases of the brain like Alzheimer’s, and others including cancer.

Israel’s Sheba Medical Center’s partnership with Israel’s Datos Health is transforming the delivery of cardiac rehabilitation programs. Datos has also partnered Israel’s Vaica Medical to add patient management facilities into its remote cardiac telemedicine app.

Israel’s Thermoguard has developed special data-gathering thermometers that flag small-but-significant peaks in body temperature. It has been testing them in kindergartens to alert staff to take early action to prevent mass classroom outbreaks from unvaccinated children.

Israel is the first country to offer vaccines to any citizen over the age of 16. It aims to vaccinate 90% of the over-50s within two weeks. Nearly two million Israelis (20% of the population) have now received two doses of the Pfizer vaccine with just 0.066% re-infections.

Nearly 3 million Israelis have now received at least the first dose of the COVID-19 vaccine and nearly 1.7 million have now received the second.  Covid infections and serious illnesses of Israelis over the age of 60 are now 60% lower than before vaccinating started. An inspiring video.

Israel’s Omnix Medical (reported previously) has been awarded €10.8 million in EU funding under the EIC Accelerator Programme, part of the EU’s Horizon 2020 research funding program. Omnix’s OMN6 peptide destroys the bacteria’s membrane, regardless of its resistance.